

## **Q-LINEA DEVELOPS PORTABLE BLOOD CULTURE TECHNOLOGY**

Q-linea AB (publ) (OMX: QLINEA), today announced that the company has started the development of a portable blood culture technology with the goal of shortening the time from sampling to correct antibiotic response. The plan is to begin an external evaluation in 2021.

"Being able to start the diagnosis immediately after sampling and using the transport time for analysis instead of throwing it away feels extremely valuable. The technology means both saved hours in the workflow and enables improved and equivalent care regardless of when and where the sample is taken", says Jonas Jarvius, CEO of Q-linea.

When diagnosing patients with blood infections, the time to a correct treatment is crucial and can provide great benefits for patients, hospitals and society. In recent years, the time to obtain an answer as to which bacterium has caused the infection has been radically shortened. As bacteria show more antibiotic resistance, the need for the same change in determining which antibiotic is effective increases. Q-linea's ASTar® system will be able to provide a quick and wide response with easy operation. However, the time for transporting blood culture bottles to the microbiology labs still in many cases prolong the important time to response. In many cases, it can today take over 10 hours for a sample to arrive at the lab, depending on when and where the sample is taken, and it is only when the sample has arrived that the diagnosis can begin.

"I am proud that Q-linea's innovative technologies will really be able to make a difference for the largest critically ill patient group in healthcare. ASTar and the technology for portable blood culture could together enable a very large improvement in diagnostics. According to our calculations, the addressable market for portable blood culture bottles in Europe and the USA is approximately SEK 15 billion," says Jonas Jarvius.

Q-linea will hold a webinar at 5 pm CET today with more information about ASTar and the portable blood culture technology. For information and registration: <https://www.qlinea.com/webinar-registration>

### **For more information, please contact:**

Jonas Jarvius, CEO, Q-linea AB  
[Jonas.Jarvius@qlinea.com](mailto:Jonas.Jarvius@qlinea.com)  
+46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB  
[Anders.Lundin@qlinea.com](mailto:Anders.Lundin@qlinea.com)  
+46 (0) 70-600 15 20

### **About Q-linea**

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit [www.qlinea.com](http://www.qlinea.com).

**Attachments**

Q-linea develops portable blood culture technology